HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolongation of the life span of cardiomyopathic hamster by the adrenergic beta 1-selective partial agonist denopamine.

Abstract
Influence of cardiotonic agents on the prognosis of heart failure depends on the individual therapeutic agents, and favorable and unfavorable effects of these agents have been reported in clinical trials. We studied the effect of the cardiotonic agent denopamine on the life span of cardiomyopathic hamsters (BIO 14.6 strain) in the heart failure period. Non-treated hamsters started to die at 40 weeks of age, and their survival rate decreased to 23.8% at the age of 65 weeks. Hamsters treated with denopamine (400 ppm in diet) from 36 weeks of age did not die until the age of 52 weeks, except in cases of accidental death. The survival rate of this group at 65 weeks of age was about 40%. Survival rates of these 2 groups were significantly different (P < 0.05) when animals with accidental death were excluded. To elucidate the mechanism of the effect of denopamine, we performed several experiments after dietary treatment with denopamine for 4 to 6 weeks from 37 weeks of age. Denopamine treatment lowered plasma levels of noradrenaline and dopamine (P < 0.05), but affected neither the cardiac contractility nor the beta-adrenoceptor density. In summary, denopamine significantly decreases the mortality of cardiomyopathic hamsters. Its effect to lower the plasma catecholamine levels may be responsible for the beneficial effect of denopamine.
AuthorsH Kurosawa, H Narita, M Kaburaki, H Yabana, H Doi, E Itogawa, M Okamoto
JournalJapanese journal of pharmacology (Jpn J Pharmacol) Vol. 72 Issue 4 Pg. 325-33 (Dec 1996) ISSN: 0021-5198 [Print] Japan
PMID9015741 (Publication Type: Journal Article)
Chemical References
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-Agonists
  • Catecholamines
  • Ethanolamines
  • denopamine
Topics
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-Agonists (therapeutic use)
  • Animals
  • Blood Pressure (drug effects)
  • Cardiomyopathies (drug therapy, pathology)
  • Catecholamines (blood)
  • Cricetinae
  • Ethanolamines (therapeutic use)
  • Heart Function Tests
  • Heart Rate (drug effects)
  • Life Expectancy
  • Male
  • Organ Size (drug effects)
  • Papillary Muscles (drug effects, metabolism)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: